Rocket Pharma Secures KRESLADI FDA Approval, $180M PRV Sale, Narrows Q1 Loss
RCKT sits 66% above its 52-week low of $2.19.
Summary
Rocket Pharmaceuticals reported a narrower net loss of $(47.6)M, or $(0.42) per share, for Q1 2026, an improvement from the prior year. More significantly, the company announced accelerated FDA approval for KRESLADI™ in March 2026 and a definitive agreement in April 2026 to sell a priority review voucher (PRV) for $180M. The FDA approval is a major commercial milestone, allowing the company to advance KRESLADI's commercialization. The $180M PRV sale provides substantial non-dilutive capital, significantly extending the company's financial runway and funding its cardiovascular pipeline, which is highly material for a company of this size. Investors will closely watch the commercial rollout of KRESLADI and the progress of its AAV cardiovascular programs, supported by this new capital.
At the time of this announcement, RCKT was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.5M. The 52-week trading range was $2.19 to $7.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.